Neurology perspectives最新文献

{"title":"Neurotoxicity of aluminium chloride and okadaic acid in zebrafish: Unravelling Alzheimer's disease model via learning and memory function evaluation","authors":"S.Z. Raduan ,&nbsp;Q.U. Ahmed ,&nbsp;M.R.A. Rusmili ,&nbsp;A.S.M. Sabere ,&nbsp;M.S. Haris ,&nbsp;M.F. Shaikh ,&nbsp;W.A.W. Sulaiman ,&nbsp;M.H. Mahmood","doi":"10.1016/j.neurop.2024.100180","DOIUrl":"10.1016/j.neurop.2024.100180","url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>Alzheimer's disease (AD) is characterised by a progressive decline in cognitive abilities, especially learning and memory. To validate the zebrafish as a suitable model organism for AD, the study examined the effects of 2 neurotoxin agents, aluminium chloride (AlCl₃) and okadaic acid (OKA). In the full experimental design, both neurotoxins were administered intraperitoneally at 3 distinct doses (low, medium, and high) twice weekly for 21 days. At 3 time-points, behavioural tasks were conducted on day 7 (short duration), day 14 (moderate duration), and day 21 (long duration). The behavioural tasks consisted of a novel tank test lasting 6 min, followed by a T-maze tank test lasting 5 min.</div></div><div><h3>Methods</h3><div>In this article, the T-maze tank test was discussed in detail to evaluate which neurotoxins and their optimal dosages are impactful in developing a zebrafish AD model towards learning and memory functions. This evaluation measured four parameters: the amount of time spent in the wrong arm, the total distance travelled in the deeper chamber, and the 3-h and 24-h inflexion ratios.</div></div><div><h3>Results</h3><div>In summary, a 100 nM dosage of OKA with a maximum of 21 days of evaluation resulted in significant (<em>P</em> <!-->&lt;<!--> <!-->.05) outcomes in all parameters evaluated. The longest duration was spent in the wrong arm, accompanied by a reduction in the total distance travelled in the deeper chamber and a decreasing pattern in the 3-h and 24-h inflexion ratios.</div></div><div><h3>Conclusion</h3><div>These observations suggest that OKA is the optimal choice of neurotoxin for a validated and optimised zebrafish AD model.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 1","pages":"Article 100180"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional cognitive disorder: Beyond pseudodementia","authors":"D.S. Marín-Medina ,&nbsp;P.A. Arenas-Vargas ,&nbsp;M. del Pilar Velásquez-Duque ,&nbsp;P.M. Bagnati","doi":"10.1016/j.neurop.2024.100179","DOIUrl":"10.1016/j.neurop.2024.100179","url":null,"abstract":"<div><h3>Introduction</h3><div>Many patients with cognitive symptoms, such as subjective memory complaints, may in fact have functional cognitive disorder.</div></div><div><h3>Development</h3><div>This review explores various aspects of functional cognitive disorder. We describe the clinical characteristics that support diagnosis. Diagnosis is not made by exclusion; rather, it is supported by positive findings, such as internal inconsistencies in cognitive symptoms. We also explore the mechanisms that could explain this condition, which include metacognitive errors, excessive self-monitoring, and abnormal emotional processing, among others. Functional cognitive disorders frequently copresent with other conditions, particularly with psychiatric disorders. We describe circumstances in which diagnostic support and neuropsychological assessment are required. Special emphasis is placed on the prognosis of this condition, which, despite the associated disability and distress, rarely progresses to dementia. Therefore, correct identification of cases and differentiation from mild cognitive impairment can help avoid unnecessary testing and reduce patient uncertainty. Treatment begins from the moment the patient is informed about their diagnosis, and is based on psychotherapy and metacognitive training.</div></div><div><h3>Conclusions</h3><div>Patients with functional cognitive disorder account for a significant percentage of consultations due to memory complaints and have particular needs. Use of specific clinical criteria allow early diagnosis and appropriate treatment.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 1","pages":"Article 100179"},"PeriodicalIF":0.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of depression in multiple sclerosis with fatigue, sleep disturbances, disability, and health-related quality of life: Outcomes of a cross-sectional study","authors":"E. Aparicio-Castro ,&nbsp;A. Candeliere-Merlicco ,&nbsp;C.M. Santa ,&nbsp;R. Villaverde-González","doi":"10.1016/j.neurop.2024.100181","DOIUrl":"10.1016/j.neurop.2024.100181","url":null,"abstract":"<div><h3>Introduction</h3><div>Depression affect individuals with multiple sclerosis (MS) more frequently compared with the general population. It can worsen the symptoms of MS, influence disability progression, and significantly reduce the quality of life (QoL).</div></div><div><h3>Method</h3><div>We investigated the prevalence of depressive symptoms in a cohort of 200 patients with MS (76% women) and their association with sleep patterns, fatigue, QoL, demographics, and other clinical characteristics in real-world settings. The study was conducted through clinical evaluations and questionnaires related to depression: Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS); fatigue: Modified Fatigue Impact Scale; sleep quality: Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale; and QoL: Multiple Sclerosis Quality of Life-54 (MSQOL-54).</div></div><div><h3>Results</h3><div>According to the BDI and HDRS, the prevalence of depressive symptoms was 40.5 and 28.27%, respectively. Patients with depressive symptoms exhibited higher disability scores, longer ambulation times, worse cognitive function in the Symbol Digit Modalities Test, and poorer sleep quality. They also had significantly higher fatigue and daytime somnolence scores, as well as lower scores on the MSQOL-54: physical (40.55 vs. 62.3; <em>P</em> <!-->&lt;<!--> <!-->.001) and mental (44.49 vs. 71.89; <em>P</em> <!-->&lt;<!--> <!-->.001) health composites. We demonstrated the correlation between depression and fatigue, as well as their negative impact on QoL in patients with MS.</div></div><div><h3>Conclusion</h3><div>This study underscores the prevalence and impact of depression in MS, emphasizing the importance of routine screening and active management of psychiatric comorbidities in individuals with MS. These findings contribute valuable insights into the complex interplay between mental health, disease variables, and QoL in MS.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 1","pages":"Article 100181"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142655173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic hyperCKemia in old age as a presentation form of a mutation in the ANO5 gene, 8 years of follow-up","authors":"R. Cuenca Hernández ,&nbsp;C. González-González ,&nbsp;G. Liaño Esteso ,&nbsp;A. Esquivel López","doi":"10.1016/j.neurop.2024.100177","DOIUrl":"10.1016/j.neurop.2024.100177","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 1","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition from paediatric to adult neurological care: What do we know?","authors":"A. Valero-Mut ,&nbsp;M.M. Rosselló-Vadell ,&nbsp;M. Caner-Faig ,&nbsp;J. Rubies-Olives ,&nbsp;M. Carmona-Belda ,&nbsp;E. Córdoba-Borrás ,&nbsp;M.A. Grimalt-Calatayud ,&nbsp;E. Miravet-Fuster","doi":"10.1016/j.neurop.2024.100174","DOIUrl":"10.1016/j.neurop.2024.100174","url":null,"abstract":"<div><h3>Introduction</h3><div>Healthcare advances have allowed an increase in the survival of paediatric patients with neurological diseases. As a result, it is increasingly common to find these patients in adult neurology consultations. The aim of this study is to evaluate the current level of consensus on the transition of neuropaediatric patients among neurology and paediatric professionals in the Balearic Islands.</div></div><div><h3>Material and methods</h3><div>We conducted an observational, analytical, cross-sectional study through an anonymous questionnaire consisting of 27 questions, which was distributed to neurologists, paediatric neurologists, hospital paediatricians, and primary care paediatricians in the healthcare network of the Balearic Islands. It was developed using Google Forms and distributed by the competent professional societies. Consensus was considered to exist for answers with 70% or more agreement.</div></div><div><h3>Results</h3><div>Responses were received from 58 professionals; 46.6% were hospital paediatricians, 29.9% were neurologists, 13.8% were paediatric neurologists, and 13.8% were primary care paediatricians. Among other issues, consensus was observed on the need for a transition programme for patients with neurological diseases. No consensus was observed regarding the duration of the transition (<em>P</em> <!-->=<!--> <!-->.029) and how long simultaneous follow-up must last after the transfer (<em>P</em> <!-->=<!--> <!-->.09).</div></div><div><h3>Conclusions</h3><div>Due to increased survival rates, there is a need to create transition programmes for paediatric patients with neurological diseases. In our study, more than 70% of professionals believed that it would be beneficial to create such programmes.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 1","pages":"Article 100174"},"PeriodicalIF":0.0,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to articles published in Neurology Perspectives","authors":"","doi":"10.1016/j.neurop.2024.100165","DOIUrl":"10.1016/j.neurop.2024.100165","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"4 4","pages":"Article 100165"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141700642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prognostic factors in acute inflammatory demyelinating polyneuropathy: Role of neurofilaments","authors":"Natalia Ruiz-Nieto,&nbsp;Antonio Belenguer-Benavides,&nbsp;Anabel Zahonero-Ferriz,&nbsp;Helena Benetó-Andrés,&nbsp;Ana Monclús-Blecua","doi":"10.1016/j.neurop.2024.100173","DOIUrl":"10.1016/j.neurop.2024.100173","url":null,"abstract":"<div><h3>Introduction</h3><div>Guillain-Barré syndrome (GBS) is an autoimmune disease that results in demyelination and axonal damage. Although the recovery is good in most patients, 20% remain significantly disabled.</div><div>Neurofilament light chain (NfL) has been established as a biomarker of axonal damage in many diseases.</div></div><div><h3>Methods</h3><div>We measured NfL, S100B, and glial fibrillary acidic protein (GFAP) concentrations from blood and cerebrospinal fluid (CSF) taken upon admission from 19 patients with a history of GBS between January 2009 and December 2019 and investigated a correlation between them and clinical outcomes.</div></div><div><h3>Results</h3><div>All patients fulfilled levels 1 or 2 of the Brighton diagnostic.</div><div>Preceding infection was reported in 11 cases (58%).</div><div>We classified 15 patients as acute inflammatory demyelinating polyneuropathy, 2 as AMAN, 1 as AMSAN, and 2 cases as Miller–Fisher syndrome.</div><div>Five patients were transferred to an ICU, with a mean stay of 13 days. Functional outcome at 6 months after discharge was good in 12 patients (70.6%).</div><div>We evaluated disease prognosis using the modified Erasmus GBS outcome score. The correlation was significant (<em>p</em> <!-->&lt;<!--> <!-->.05) in the case of NfL in serum and CSF and GFAP in CSF (<em>r</em> <!-->=<!--> <!-->0.472 for serum NfL, 0.576 for CSF NfL, and 0.544 for CSF GFAP).</div></div><div><h3>Conclusions</h3><div>We confirm the finding of elevated levels of NfL, GFAP, and S100B in CSF and plasma in the acute phase of GBS.</div><div>We can point out that their value has a certain relationship with the severity of the disease and prognosis, and that in some way, they have an influence, but we would lack more information to make good predictions.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"4 4","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of mortality in dementia: A systematic review and meta-analysis","authors":"P.T.M. González ,&nbsp;L.M. Vieira ,&nbsp;A.P.Y. Sarmiento ,&nbsp;J.S. Ríos ,&nbsp;M.A.S. Alarcón ,&nbsp;M.A.O. Guerrero","doi":"10.1016/j.neurop.2024.100175","DOIUrl":"10.1016/j.neurop.2024.100175","url":null,"abstract":"<div><h3>Introduction</h3><div>Identifying predictors of dementia and differences in mortality rates between dementia subtypes could contribute to the development of preventive strategies.</div></div><div><h3>Aims</h3><div>To identify risk factors for mortality in patients with dementia and to determine the incidence of mortality.</div></div><div><h3>Methodology</h3><div>We conducted a systematic review and meta-analysis, following the PRISMA 2020 statement. The search was performed on the PubMed/Medline, Embase, and BIREME/LILACS databases.</div></div><div><h3>Results</h3><div>Our meta-analysis included 15 observational studies, reporting data from 177 663 patients with dementia. The following predictors of mortality were identified: male sex (OR: 1.40 [95% CI, 1.22–1.62]), white ethnicity (OR: 1.50 [95% CI, 1.30–1.73]), Alzheimer disease (OR: 1.26 [95% CI, 1.03–1.53]), diabetes mellitus (OR: 1.29 [95% CI, 1.21–1.39]), stroke (OR: 1.25 [95% CI, 1.10–1.41]), pneumonia (OR: 3.00 [95% CI, 2.26–4.00]), Charlson Comorbidity Index (standardised mean difference (SMD): 0.21 [95% CI, 0.18–0.23]), supplemental oxygen therapy (OR: 9.97 [95% CI, 9.49–10.46]), and number of medications (SMD: 0.24 [95% CI, 0.21–0.26]). In patients with Alzheimer disease, the mortality rate was 35% (95% CI, 23%–46%), with a mean follow-up time of 34 months. The incidence of mortality in patients with other types of dementia was 48% (95% CI, 38%–56%), with a mean follow-up time of 70 months.</div></div><div><h3>Conclusions</h3><div>The incidence of mortality was higher in patients with dementia other than Alzheimer disease. The type of dementia and the risk factors described should be taken into account when developing prevention strategies.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"4 4","pages":"Article 100175"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral venous sinus thrombosis after Russell's viper (Daboia russelii) envenomation: A case report","authors":"U. Biswas ,&nbsp;M. León-Ruiz ,&nbsp;R. Ghosh ,&nbsp;A. Bhattacharjee ,&nbsp;S.R. Mondal ,&nbsp;J. Benito-León","doi":"10.1016/j.neurop.2024.100176","DOIUrl":"10.1016/j.neurop.2024.100176","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"4 4","pages":"Article 100176"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142527185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bartonella henselae neuroretinitis: A rare manifestation of cat-scratch disease","authors":"I.B. Ventura ,&nbsp;M.J. Gaia ,&nbsp;P.M. Martins ,&nbsp;M.F. Santos","doi":"10.1016/j.neurop.2024.100172","DOIUrl":"10.1016/j.neurop.2024.100172","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"4 4","pages":"Article 100172"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142426076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}